[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![moneyvize_app Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1716465783570890752.png) Moneyvize [@moneyvize_app](/creator/twitter/moneyvize_app) on x XX followers
Created: 2025-07-24 00:32:26 UTC

Check this earnings summary for $BSX from Login now for powerful analysis! ✨
Boston Scientific delivered a strong quarter exceeding expectations with robust organic revenue growth and adjusted EPS. Key drivers include the Cardiovascular segment, the success of WATCHMAN, and the launch of FARAPULSE. While the ACURATE discontinuation and tariff impacts present challenges, the company raised its full-year guidance, reflecting confidence in its portfolio and strategic initiatives. The company is well-positioned for continued growth with a focus on innovation and strategic acquisitions. Electrophysiology sales grew XX% due to the FARAPULSE launch.
Q3'25 Guidance for organic growth is XX% to 14%.  #Moneyvize #Earnings #Healthcare #Stocks #EarningsReport #EarningsSeason #Investing #aipowered #BSX

![](https://pbs.twimg.com/media/GwlSl7paoAAeUf6.jpg)

XX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1948179429337026571/c:line.svg)

**Related Topics**
[tariffs](/topic/tariffs)
[eps](/topic/eps)
[quarterly earnings](/topic/quarterly-earnings)
[robust](/topic/robust)
[login](/topic/login)
[$bsx](/topic/$bsx)
[boston scientific](/topic/boston-scientific)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/moneyvize_app/status/1948179429337026571)